Shuvolina Mukherjee

Dr. Shuvolina Mukherjee

Lunds universitet - Sweden
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2016 in Proteomics
Verified
Journal Article
Closed access
PDF file
AAApurva Atak
Apurva Atak
Shuvolina MukherjeeShuvolina Mukherjee
Shuvolina Mukherjee
RJRekha Jain
Rekha Jain
SGShabarni Gupta
Shabarni Gupta
VSVedita Anand Singh
Vedita Anand Singh
Sanjeeva SrivastavaSanjeeva Srivastava
Sanjeeva Srivastava

21 November 2014 in Proteomics
Verified
Journal Article
Closed access
PDF file
SSSamridhi Sharma
Samridhi Sharma
SRSandipan Ray
Sandipan Ray
Shuvolina MukherjeeShuvolina Mukherjee
Shuvolina Mukherjee
AMAliasgar Moiyadi
Aliasgar Moiyadi
ESEpari Sridhar
Epari Sridhar
Sanjeeva SrivastavaSanjeeva Srivastava
Sanjeeva Srivastava

8 October 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SCSreedhar Chinnaswamy
Sreedhar Chinnaswamy
SCSnehajyoti Chatterjee
Snehajyoti Chatterjee
RBRamachandran Boopathi
Ramachandran Boopathi
Shuvolina MukherjeeShuvolina Mukherjee
Shuvolina Mukherjee
SBSamsiddhi Bhattacharjee
Samsiddhi Bhattacharjee
TKTapas K Kundu
Tapas K Kundu
Persistence of hepatitis C virus (HCV) infection is observed only in a subset of infected individuals and among them only some respond to treatment. Genome-wide association studies (GWAS) carried out around the world identified single nucleotide polymorphisms (SNPs) in the IL28B locus that are strongly associated with both HCV clearance and treatment response. The functional significance of these associations however, is not clear. In this report we show that an SNP rs28416813 in the distal promoter region of IL28B that is in close proximity to a non-consensus NF-κB-binding site affects downstream reporter gene expression. The effect is likely due to differential binding of NF-κB at the non-consensus site. The non-protective allele showed a reduction in luciferase reporter gene expression compared to the protective allele in HEK293T cells under different experimental conditions including treatment with tumor necrosis factor alpha (TNF-α) and 5′ triphosphorylated dsRNA. Furthermore, the HCV RNA polymerase was able to induce transcription from the IL28B promoter in a RIG-I-dependent manner. This induction was influenced by the alleles present at rs28416813. We also demonstrate strong linkage disequilibrium between rs28416813 and another important SNP rs12979860 in two ethnic populations. These results suggest possible mechanisms by which SNPs at the IL28B locus influence spontaneous clearance and treatment response in chronic HCV infections.

10 April 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
SGShabarni Gupta
Shabarni Gupta
Shuvolina MukherjeeShuvolina Mukherjee
Shuvolina Mukherjee
PSParvez Syed
Parvez Syed
NPNarendra Goud Pandala
Narendra Goud Pandala
SCSaket Choudhary
Saket Choudhary
Sanjeeva SrivastavaSanjeeva Srivastava
Sanjeeva Srivastava
Evaluation of autoantibody signatures in meningioma patients using human proteome arrays

26 August 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
Shuvolina MukherjeeShuvolina Mukherjee
Shuvolina Mukherjee
DBDeeptarup Biswas
Deeptarup Biswas
RGRucha Gadre
Rucha Gadre
PJPooja Jain
Pooja Jain
NSNelofer Syed
Nelofer Syed
Sanjeeva SrivastavaSanjeeva Srivastava
Sanjeeva Srivastava
Meningiomas are one of the most prevalent primary brain tumors. Our study aims to obtain mechanistic insights of meningioma pathobiology using mass spectrometry-based label-free quantitative proteome analysis to identifying druggable targets and perturbed pathways for therapeutic intervention. Label-free based proteomics study was done from peptide samples of 21 patients and 8 non-tumor controls which were followed up with Phosphoproteomics to identify the kinases and phosphorylated components of the perturbed pathways. In silico approaches revealed perturbations in extracellular matrix remodeling and associated cascades. To assess the extent of influence of Integrin and PI3K-Akt pathways, we used an Integrin Linked Kinase inhibitor on patient-derived meningioma cell line and performed a transcriptomic analysis of the components. Furthermore, we designed a Targeted proteomics assay which to the best of our knowledge for very first-time enables identification of peptides from 54 meningioma patients via SRM assay to validate the key proteins emerging from our study. This resulted in the identification of peptides from CLIC1, ES8L2, and AHNK many of which are receptors and kinases and are difficult to be characterized using conventional approaches. Furthermore, we were also able to monitor transitions for proteins like NEK9 and CKAP4 which have been reported to be associated with meningioma pathobiology. We believe, this study can aid in designing peptide-based validation assays for meningioma patients as well as IHC studies for clinical applications.

25 May 2021 in Proteomes
Verified
Journal Article
Open access
PDF file
Shuvolina MukherjeeShuvolina Mukherjee
Shuvolina Mukherjee
KSKarin Sundfeldt
Karin Sundfeldt
CBCarl Borrebaeck
Carl Borrebaeck
MJMagnus E Jakobsson
Magnus E Jakobsson
Despite recent technological advancements allowing the characterization of cancers at a molecular level along with biomarkers for cancer diagnosis, the management of ovarian cancers (OC) remains challenging. Proteins assume functions encoded by the genome and the complete set of proteins, termed the proteome, reflects the health state. Comprehending the circulatory proteomic profiles for OC subtypes, therefore, has the potential to reveal biomarkers with clinical utility concerning early diagnosis or to predict response to specific therapies. Furthermore, characterization of the proteomic landscape of tumor-derived tissue, cell lines, and PDX models has led to the molecular stratification of patient groups, with implications for personalized therapy and management of drug resistance. Here, we review single and multiple marker panels that have been identified through proteomic investigations of patient sera, effusions, and other biospecimens. We discuss their clinical utility and implementation into clinical practice.